Wall Street analysts expect Pacira Pharmaceuticals Inc (NASDAQ:PCRX) to report $80.43 million in sales for the current fiscal quarter, according to Zacks. Eight analysts have provided estimates for Pacira Pharmaceuticals’ earnings, with the highest sales estimate coming in at $85.00 million and the lowest estimate coming in at $78.14 million. Pacira Pharmaceuticals reported sales of $67.34 million in the same quarter last year, which indicates a positive year over year growth rate of 19.4%. The business is scheduled to report its next quarterly earnings results on Wednesday, November 14th.

On average, analysts expect that Pacira Pharmaceuticals will report full-year sales of $327.89 million for the current fiscal year, with estimates ranging from $324.50 million to $329.90 million. For the next fiscal year, analysts forecast that the business will post sales of $377.21 million, with estimates ranging from $351.23 million to $412.19 million. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for Pacira Pharmaceuticals.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings results on Thursday, August 2nd. The company reported $0.24 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.37. Pacira Pharmaceuticals had a negative net margin of 3.64% and a negative return on equity of 0.39%. The company had revenue of $84.10 million for the quarter, compared to the consensus estimate of $77.53 million. During the same quarter in the previous year, the company earned ($0.11) EPS. Pacira Pharmaceuticals’s quarterly revenue was up 18.6% compared to the same quarter last year.

A number of research firms recently issued reports on PCRX. Royal Bank of Canada set a $55.00 target price on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, September 19th. ValuEngine downgraded shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Canaccord Genuity set a $49.00 target price on shares of Pacira Pharmaceuticals and gave the company a “hold” rating in a research report on Tuesday. Stifel Nicolaus began coverage on shares of Pacira Pharmaceuticals in a research report on Thursday, September 13th. They set a “sell” rating and a $41.00 target price on the stock. Finally, TheStreet upgraded shares of Pacira Pharmaceuticals from a “d+” rating to a “c” rating in a research report on Friday, August 10th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have issued a buy rating to the company’s stock. Pacira Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $47.82.

In other Pacira Pharmaceuticals news, VP Lauren Bullaro Riker sold 1,667 shares of the company’s stock in a transaction on Wednesday, August 22nd. The shares were sold at an average price of $44.48, for a total transaction of $74,148.16. Following the transaction, the vice president now owns 10,474 shares in the company, valued at $465,883.52. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Kristen Marie Williams sold 4,773 shares of the company’s stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $47.04, for a total transaction of $224,521.92. Following the transaction, the chief accounting officer now owns 22,374 shares in the company, valued at approximately $1,052,472.96. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 40,502 shares of company stock worth $1,913,864. Corporate insiders own 5.90% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PCRX. US Bancorp DE grew its stake in shares of Pacira Pharmaceuticals by 53.8% in the 1st quarter. US Bancorp DE now owns 4,292 shares of the company’s stock worth $134,000 after acquiring an additional 1,501 shares in the last quarter. Fisher Asset Management LLC grew its stake in shares of Pacira Pharmaceuticals by 29.6% in the 1st quarter. Fisher Asset Management LLC now owns 6,848 shares of the company’s stock worth $213,000 after acquiring an additional 1,566 shares in the last quarter. Cubist Systematic Strategies LLC grew its stake in shares of Pacira Pharmaceuticals by 1,925.8% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 6,665 shares of the company’s stock worth $214,000 after acquiring an additional 6,336 shares in the last quarter. Xact Kapitalforvaltning AB bought a new stake in shares of Pacira Pharmaceuticals in the 2nd quarter worth $219,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Pacira Pharmaceuticals in the 2nd quarter worth $312,000.

Shares of Pacira Pharmaceuticals stock traded down $0.07 during trading on Friday, reaching $45.34. 670,060 shares of the company traded hands, compared to its average volume of 843,915. The company has a quick ratio of 7.79, a current ratio of 8.58 and a debt-to-equity ratio of 0.98. Pacira Pharmaceuticals has a 1-year low of $26.95 and a 1-year high of $52.60. The company has a market capitalization of $2.01 billion, a PE ratio of -78.17 and a beta of 1.86.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Further Reading: Technical Analysis

Get a free copy of the Zacks research report on Pacira Pharmaceuticals (PCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.